1. Phylogeny  
   Tyrosine‐protein kinase JAK2 belongs to the Janus kinase family – a group of four non‐receptor tyrosine kinases comprising JAK1, JAK2, JAK3, and TYK2. Comparative analyses of the human kinome have shown that JAK2 is evolutionarily conserved among vertebrates, with orthologs identified spanning from early metazoans to mammals. The domain architecture of JAK family members, featuring an active kinase domain (JH1) coupled with a regulatory pseudokinase domain (JH2), is highly conserved. This dual‐domain arrangement, which also includes N-terminal FERM and SH2-like domains, is thought to have evolved from an ancestral kinase gene and maintained under strong selective pressure owing to its indispensable role in modulating cytokine receptor signaling (babon2014themolecularregulation pages 1-3). In addition, these N-terminal domains are critical for receptor binding and ensuring the correct spatial orientation of JAK2 at the cell membrane; they are uniformly present in orthologs across species, emphasizing the fundamental importance of JAK2 in pathways regulating hematopoiesis and immune responses (karjalainen2016interactionsofjak2 pages 8-11, mingione2023allostericregulationand pages 1-3). Tissue expression studies in mammals further support the notion that JAK2 is ubiquitously expressed, thereby playing a central role in mediating signaling events in a wide variety of cell types (kwon2022moleculardissectionof pages 1-2).
2. Reaction Catalyzed  
   JAK2 catalyzes a classic tyrosine phosphorylation reaction. In the active kinase state, it facilitates the transfer of the γ-phosphate group from adenosine triphosphate (ATP) to a designated tyrosine residue on substrate proteins. The reaction can be formally represented by the equation:  
     ATP + [protein]-L-tyrosine → ADP + [protein]-L-tyrosine-phosphate + H+  
   This reaction is carried out within a ternary complex where ATP and its protein substrate are bound simultaneously to the catalytic site of JAK2. The efficient transfer of the phosphate group leads to the functional modification of the substrate, an event that is critical for downstream signaling. Phosphorylation of receptor cytoplasmic domains creates docking sites that are essential for the recruitment and subsequent phosphorylation of STAT (signal transducer and activator of transcription) proteins, enabling them to form homo- or heterodimers and translocate to the nucleus (matsuda2004determinationofthe pages 1-6, babon2014themolecularregulation pages 1-3, mingione2023allostericregulationand pages 1-3).
3. Cofactor Requirements  
   The catalytic activity of JAK2 is strictly dependent on the presence of divalent metal ions. Magnesium (Mg²⁺) serves as the primary cofactor that coordinates with the phosphate groups of ATP and aids in the stabilization of its binding within the catalytic cleft of the kinase domain. This coordination is a prerequisite for the proper alignment of the reactive hydroxyl group of substrate tyrosine residues for phosphate transfer. Although Mg²⁺ is the predominant cofactor in physiological conditions, other divalent cations such as manganese (Mn²⁺) have been observed to support kinase activity under experimental conditions. However, under normal cellular conditions, Mg²⁺ plays the critical role required for optimal enzyme function (matsuda2004determinationofthe pages 1-6, endicott2012thestructuralbasis pages 26-27, mingione2023allostericregulationand pages 1-3).
4. Substrate Specificity  
   JAK2 exhibits specificity for phosphorylating tyrosine residues within particular sequence contexts on its substrate proteins. Its primary substrates are the cytoplasmic domains of type I and type II cytokine receptors and the STAT transcription factors. Upon cytokine binding, specific tyrosine residues on these receptor tails become phosphorylated, thereby creating binding sites for SH2-domain-containing proteins. Although a single consensus motif for JAK2 substrates has not been uniformly defined, evidence from peptide microarray analyses suggests that the intrinsic substrate recognition of JAK2 involves residues flanking the target tyrosine that favor binding and phosphorylation (sanz2011analysisofjak2 pages 10-11, deng2014globalanalysisof pages 1-4). For example, phosphorylation events on the erythropoietin receptor (EPOR) facilitate the recruitment and subsequent phosphorylation of STAT5, a key step in erythropoiesis. Additionally, JAK2 phosphorylates other substrates such as CDKN1B, which is integral to the regulation of the cell cycle, and histone H3 at tyrosine 41 (H3Y41ph), which modulates chromatin structure by affecting the binding of chromatin-associated proteins such as CBX5 (hammaren2015atpbindingto pages 6-6).
5. Structure  
   The three-dimensional structure of JAK2 is defined by its modular and multidomain organization, which underpins its dual functions—receptor binding and catalytic activation. At the extreme N-terminus, JAK2 contains a FERM domain that is critical for binding to the cytoplasmic tails of cytokine receptors. This domain is essential for the proper localization of the kinase at the cell membrane and for the formation of receptor–kinase complexes required for downstream signaling (babon2014themolecularregulation pages 1-3). Adjacent to the FERM domain is an SH2-like domain; although it is structurally similar to canonical SH2 domains, its primary role in JAK2 is to contribute to the stabilization of the receptor–kinase complex rather than to mediate classic phosphotyrosine interactions (hubbard2018mechanisticinsightsinto pages 1-2).

Central to JAK2’s structure is the pseudokinase domain (JH2). Despite its structural similarity to active kinase domains, the JH2 domain lacks several catalytic residues and thus displays only weak kinase activity. Nevertheless, it retains the ability to bind ATP and serves a critical regulatory function by autoinhibiting the catalytic kinase domain (JH1). This intramolecular interaction between JH2 and JH1 is a defining feature of Janus kinases and is essential for maintaining low basal activity in the absence of cytokine stimulation (hubbard2018mechanisticinsightsinto pages 1-2, mingione2023allostericregulationand pages 7-9).

The C-terminal region of JAK2 is occupied by the active kinase domain (JH1), which spans roughly 300 amino acids and adopts the conventional bilobal architecture characteristic of protein kinases. The smaller N-terminal lobe of JH1 is composed primarily of β-strands and contains a glycine-rich loop that is crucial for ATP binding. In contrast, the larger C-terminal lobe is predominantly α-helical and hosts the catalytic loop along with the activation segment. Key catalytic features of the kinase domain include the DFG motif located within the activation loop, which coordinates Mg²⁺ ions necessary for ATP binding, and a conserved C-helix that forms a salt bridge with a lysine located in the VAIK motif—both of which stabilize the active conformation of the domain (matsuda2004determinationofthe pages 6-11, endicott2012thestructuralbasis pages 26-27).

A distinctive structural aspect of JAK2 is the tandem arrangement of the pseudokinase (JH2) and kinase (JH1) domains. This arrangement not only allows for the regulation of JH1 by JH2 but also facilitates allosteric interactions mediated through the intervening SH2–JH2 linker region. These interdomain contacts are crucial for modulating ATP-binding affinity and determining the sensitivity of the kinase to small-molecule inhibitors. The high-resolution structures, derived from crystallographic studies and supported by computational models, emphasize the dynamic nature of these interdomain interactions that enable JAK2 to be precisely tuned for rapid activation in response to cytokine stimulation (mingione2023allostericregulationand pages 7-9, kwon2022moleculardissectionof pages 1-2).

1. Regulation  
   JAK2 is regulated through a combination of post-translational modifications and intramolecular domain interactions that ensure its activity is tightly controlled under basal conditions. A key regulatory mechanism involves the autophosphorylation of tyrosine residues within the activation loop of the kinase domain (JH1). In particular, phosphorylation of tyrosine 1007 is critical for releasing autoinhibitory constraints and stabilizing the active conformation of JAK2, thereby facilitating efficient substrate phosphorylation (babon2014themolecularregulation pages 1-3, matsuda2004determinationofthe pages 6-11).

The pseudokinase domain (JH2) plays a central regulatory role by exerting a negative influence on the catalytic activity of the JH1 domain. Under resting conditions, the JH2 domain interacts with JH1 to maintain a low basal level of kinase activity. This autoinhibitory interaction is mediated via an intricate network of contact interfaces involving the SH2–JH2 linker region that modulates ATP binding. Disruption of these interactions, as observed in the commonly occurring V617F mutation within the JH2 domain, can lead to loss of autoinhibition and constitutive activation of JAK2. Such dysregulation is associated with several myeloproliferative disorders (hubbard2018mechanisticinsightsinto pages 5-6, barua2009abipolarclamp pages 7-8).

Additional layers of regulation are provided by other post-translational modifications. Phosphorylation events on residues outside the activation loop also contribute to fine-tuning JAK2 activity. For example, phosphorylation of specific tyrosines within domains involved in receptor docking can modulate the stability of the receptor–JAK2 complex, thereby indirectly influencing downstream signaling events. Regulatory mechanisms also include ubiquitination and dephosphorylation, which serve to modulate the turnover and deactivation of JAK2 under various physiological conditions. Collectively, these regulatory strategies ensure that JAK2 remains tightly controlled until receptor engagement triggers the necessary conformational changes for full enzymatic activation (babon2014themolecularregulation pages 1-3, mingione2023allostericregulationand pages 7-9, matsuda2004determinationofthe pages 1-6).

1. Function  
   JAK2 occupies a central role in mediating signal transduction cascades that are initiated by both type I and type II cytokine receptors. Upon binding of cytokines to receptors such as the erythropoietin receptor (EPOR), growth hormone receptor (GHR), prolactin receptor (PRLR), leptin receptor (LEPR), or thrombopoietin receptor (MPL/TPOR), JAK2 becomes activated through receptor-induced dimerization. This dimerization event promotes trans-phosphorylation of the kinase domains, which in turn phosphorylate specific tyrosine residues on the receptor’s cytoplasmic tails. These phosphorylated tyrosine motifs then serve as docking sites for STAT transcription factors, which are further phosphorylated by JAK2. The activated STATs dimerize, translocate to the nucleus, and regulate transcription of target genes involved in hematopoiesis, immune regulation, cell proliferation, and survival (babon2014themolecularregulation pages 1-3, matsuda2004determinationofthe pages 1-6).

Apart from its well-established role in the JAK/STAT signaling pathway, JAK2 is also implicated in several other cellular functions. For example, JAK2 phosphorylates CDKN1B, a cyclin-dependent kinase inhibitor, thereby linking cytokine receptor signaling to cell cycle regulation. Moreover, JAK2 mediates angiotensin II-induced phosphorylation of ARHGEF1, thus playing a part in stress and vascular responsiveness (deng2014globalanalysisof pages 1-4). In the nuclear compartment, JAK2 phosphorylates histone H3 at tyrosine 41 (H3Y41ph), which alters chromatin architecture by preventing the binding of chromobox protein CBX5 (HP1α). This histone modification is an important mechanism by which JAK2 can influence gene expression directly at the chromatin level. In addition, JAK2 has been linked to the regulation of ion channel activity, as evidenced by its role in up-regulating the potassium voltage-gated channel KCNA3, thereby integrating cytokine signaling with changes in membrane excitability (hammaren2015atpbindingto pages 6-6, deng2014globalanalysisof pages 1-4). JAK2 is widely expressed in numerous tissues, which further underscores its pivotal role in both innate and adaptive immune responses as well as in the regulation of blood cell production.

1. Other Comments  
   Given its central role in cytokine receptor signaling, the appropriate regulation of JAK2 is essential; dysregulation can have significant pathological consequences. One of the most well-known mutations that affects JAK2 regulation is the V617F mutation within the pseudokinase domain. This mutation compromises the autoinhibitory function of JH2, leading to constitutive activation of the kinase, and is a defining molecular marker in various myeloproliferative neoplasms (MPNs) such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis (barua2009abipolarclamp pages 7-8, hubbard2018mechanisticinsightsinto pages 5-6).

The clinical importance of JAK2 has spurred the development of several small molecule inhibitors targeting its ATP-binding site. Agents such as ruxolitinib are ATP-competitive inhibitors that have been clinically approved for the treatment of myelofibrosis and other related MPNs (kwon2022moleculardissectionof pages 1-2, mingione2023allostericregulationand pages 7-9). Beyond these first-generation inhibitors, ongoing research is focused on developing next-generation compounds that target allosteric sites or interdomain interfaces. This approach, which may involve the pseudokinase domain or the SH2–JH2 linker region, holds promise for achieving higher specificity and lowering side effects when compared to classical ATP-competitive inhibition strategies.

Furthermore, extensive studies have explored combination therapy approaches that target multiple regulatory nodes within the JAK2 signaling network, emphasizing the potential to modulate its activity in a more finely tuned manner. These efforts underscore the significance of integrating structural, biochemical, and pharmacological insights into the design of therapeutic interventions aimed at fine-tuning, rather than completely abolishing, JAK2 activity within pathological contexts.

1. References
2. Babon, J.J. et al. The molecular regulation of Janus kinase (JAK) activation. The Biochemical Journal, 462(1):1-13, Aug 2014. (babon2014themolecularregulation pages 1-3)
3. Barua, D., Faeder, J.R., and Haugh, J.M. A bipolar clamp mechanism for activation of JAK-family protein tyrosine kinases. PLoS Computational Biology, 5:e1000364, Apr 2009. (barua2009abipolarclamp pages 7-8)
4. Deng, Y. et al. Global analysis of human nonreceptor tyrosine kinase specificity using high-density peptide microarrays. Journal of Proteome Research, 13:4339-4346, Aug 2014. (deng2014globalanalysisof pages 1-4)
5. Endicott, J.A., Noble, M.E.M., and Johnson, L.N. The structural basis for control of eukaryotic protein kinases. Annual Review of Biochemistry, 81:587-613, Jul 2012. (endicott2012thestructuralbasis pages 26-27)
6. Hammaren, H.M. et al. ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation. Proceedings of the National Academy of Sciences, 112:4642-4647, Mar 2015. (hammaren2015atpbindingto pages 6-6)
7. Hubbard, S.R. Mechanistic insights into regulation of JAK2 tyrosine kinase. Frontiers in Endocrinology, 8:361, Jan 2018. (hubbard2018mechanisticinsightsinto pages 1-2)
8. Hubbard, S.R. Mechanistic insights into regulation of JAK2 tyrosine kinase. Frontiers in Endocrinology, 8:361, Jan 2018. (hubbard2018mechanisticinsightsinto pages 5-6)
9. Karjalainen, A. Interactions of JAK2 pseudokinase and kinase domains in health and disease. (karjalainen2016interactionsofjak2 pages 8-11)
10. Karjalainen, A. Interactions of JAK2 pseudokinase and kinase domains in health and disease. (karjalainen2016interactionsofjak2a pages 8-11)
11. Kwon, S. Molecular dissection of Janus kinases as drug targets for inflammatory diseases. Frontiers in Immunology, Dec 2022. (kwon2022moleculardissectionof pages 1-2)
12. Matsuda, T. et al. Determination of the transphosphorylation sites of JAK2 kinase. Biochemical and Biophysical Research Communications, 325:586-594, Dec 2004. (matsuda2004determinationofthe pages 1-6, pages 6-11)
13. Min, X. et al. Structural and functional characterization of the JH2 pseudokinase domain of TYK2. Journal of Biological Chemistry, 290:27261-27270, Nov 2015. (min2015structuralandfunctional pages 1-2)
14. Mingione, V.R. et al. Allosteric regulation and inhibition of protein kinases. Biochemical Society Transactions, 51:373-385, Feb 2023. (mingione2023allostericregulationand pages 1-3, mingione2023allostericregulationand pages 7-9)
15. Sanz, A. et al. Analysis of JAK2 catalytic function by peptide microarrays: the role of the JH2 domain and V617F mutation. PLoS ONE, 6:e18522, Apr 2011. (sanz2011analysisofjak2 pages 10-11)

References

1. (babon2014themolecularregulation pages 1-3): Jeffrey J. Babon, Isabelle S. Lucet, James M. Murphy, Nicos A. Nicola, and Leila N. Varghese. The molecular regulation of janus kinase (jak) activation. The Biochemical journal, 462 1:1-13, Aug 2014. URL: https://doi.org/10.1042/bj20140712, doi:10.1042/bj20140712. This article has 410 citations.
2. (barua2009abipolarclamp pages 7-8): Dipak Barua, James R. Faeder, and Jason M. Haugh. A bipolar clamp mechanism for activation of jak-family protein tyrosine kinases. PLoS Computational Biology, 5:e1000364, Apr 2009. URL: https://doi.org/10.1371/journal.pcbi.1000364, doi:10.1371/journal.pcbi.1000364. This article has 28 citations and is from a highest quality peer-reviewed journal.
3. (deng2014globalanalysisof pages 1-4): Yang Deng, Nilda L. Alicea-Velázquez, Ludovic Bannwarth, Soili I. Lehtonen, Titus J. Boggon, Heung-Chin Cheng, Vesa P. Hytönen, and Benjamin E. Turk. Global analysis of human nonreceptor tyrosine kinase specificity using high-density peptide microarrays. Journal of Proteome Research, 13:4339-4346, Aug 2014. URL: https://doi.org/10.1021/pr500503q, doi:10.1021/pr500503q. This article has 53 citations and is from a peer-reviewed journal.
4. (endicott2012thestructuralbasis pages 26-27): Jane A. Endicott, Martin E.M. Noble, and Louise N. Johnson. The structural basis for control of eukaryotic protein kinases. Annual Review of Biochemistry, 81:587-613, Jul 2012. URL: https://doi.org/10.1146/annurev-biochem-052410-090317, doi:10.1146/annurev-biochem-052410-090317. This article has 523 citations and is from a domain leading peer-reviewed journal.
5. (hammaren2015atpbindingto pages 6-6): Henrik M. Hammarén, Daniela Ungureanu, Jean Grisouard, Radek C. Skoda, Stevan R. Hubbard, and Olli Silvennoinen. Atp binding to the pseudokinase domain of jak2 is critical for pathogenic activation. Proceedings of the National Academy of Sciences, 112:4642-4647, Mar 2015. URL: https://doi.org/10.1073/pnas.1423201112, doi:10.1073/pnas.1423201112. This article has 117 citations.
6. (hubbard2018mechanisticinsightsinto pages 1-2): Stevan R. Hubbard. Mechanistic insights into regulation of jak2 tyrosine kinase. Frontiers in Endocrinology, Jan 2018. URL: https://doi.org/10.3389/fendo.2017.00361, doi:10.3389/fendo.2017.00361. This article has 118 citations and is from a peer-reviewed journal.
7. (hubbard2018mechanisticinsightsinto pages 5-6): Stevan R. Hubbard. Mechanistic insights into regulation of jak2 tyrosine kinase. Frontiers in Endocrinology, Jan 2018. URL: https://doi.org/10.3389/fendo.2017.00361, doi:10.3389/fendo.2017.00361. This article has 118 citations and is from a peer-reviewed journal.
8. (karjalainen2016interactionsofjak2 pages 8-11): A KARJALAINEN. Interactions of jak2 pseudokinase and kinase do-mains in health and disease. Unknown journal, 2016.
9. (karjalainen2016interactionsofjak2a pages 8-11): A KARJALAINEN. Interactions of jak2 pseudokinase and kinase do-mains in health and disease. Unknown journal, 2016.
10. (kwon2022moleculardissectionof pages 1-2): Sunghark Kwon. Molecular dissection of janus kinases as drug targets for inflammatory diseases. Frontiers in Immunology, Dec 2022. URL: https://doi.org/10.3389/fimmu.2022.1075192, doi:10.3389/fimmu.2022.1075192. This article has 13 citations and is from a peer-reviewed journal.
11. (matsuda2004determinationofthe pages 1-6): Tadashi Matsuda, Jian Feng, Bruce A. Witthuhn, Yuichi Sekine, and James N. Ihle. Determination of the transphosphorylation sites of jak2 kinase. Biochemical and Biophysical Research Communications, 325:586-594, Dec 2004. URL: https://doi.org/10.1016/j.bbrc.2004.10.071, doi:10.1016/j.bbrc.2004.10.071. This article has 66 citations and is from a peer-reviewed journal.
12. (matsuda2004determinationofthe pages 6-11): Tadashi Matsuda, Jian Feng, Bruce A. Witthuhn, Yuichi Sekine, and James N. Ihle. Determination of the transphosphorylation sites of jak2 kinase. Biochemical and Biophysical Research Communications, 325:586-594, Dec 2004. URL: https://doi.org/10.1016/j.bbrc.2004.10.071, doi:10.1016/j.bbrc.2004.10.071. This article has 66 citations and is from a peer-reviewed journal.
13. (min2015structuralandfunctional pages 1-2): Xiaoshan Min, Daniela Ungureanu, Sarah Maxwell, Henrik Hammarén, Steve Thibault, Ellin-Kristina Hillert, Merrill Ayres, Brad Greenfield, John Eksterowicz, Chris Gabel, Nigel Walker, Olli Silvennoinen, and Zhulun Wang. Structural and functional characterization of the jh2 pseudokinase domain of jak family tyrosine kinase 2 (tyk2). Journal of Biological Chemistry, 290:27261-27270, Nov 2015. URL: https://doi.org/10.1074/jbc.m115.672048, doi:10.1074/jbc.m115.672048. This article has 108 citations and is from a domain leading peer-reviewed journal.
14. (mingione2023allostericregulationand pages 1-3): Victoria R. Mingione, YiTing Paung, Ian R. Outhwaite, and Markus A. Seeliger. Allosteric regulation and inhibition of protein kinases. Biochemical Society Transactions, 51:373-385, Feb 2023. URL: https://doi.org/10.1042/bst20220940, doi:10.1042/bst20220940. This article has 19 citations and is from a peer-reviewed journal.
15. (mingione2023allostericregulationand pages 7-9): Victoria R. Mingione, YiTing Paung, Ian R. Outhwaite, and Markus A. Seeliger. Allosteric regulation and inhibition of protein kinases. Biochemical Society Transactions, 51:373-385, Feb 2023. URL: https://doi.org/10.1042/bst20220940, doi:10.1042/bst20220940. This article has 19 citations and is from a peer-reviewed journal.